MannKind price target raised to $15 from $12 at Brinson Patrick Brinson Patrick raised its price target for MannKind shares to $15 citing the FDA Approval of Afrezza for diabetes. The firm says the labeling, REMS program, and post-marketing requirements exceeded its expectations. It keeps an Outperform rating on the stock.
News For MNKD From The Last 14 Days
Check below for free stories on MNKD the last two weeks.